mTBI

Shutterstock 1063712879 Scaled

A Comparative Analysis of the ACRM Diagnostic Criteria and Mayo Classification System for Traumatic Brain Injury: Strengths, Limitations, and Clinical Accuracy

Introduction Traumatic brain injuries (TBIs) remain a significant public health challenge, affecting millions worldwide each year. Among these, mild traumatic […]

A Comparative Analysis of the ACRM Diagnostic Criteria and Mayo Classification System for Traumatic Brain Injury: Strengths, Limitations, and Clinical Accuracy Read Post »

6e5c27c1 085c 4563 9cd5 E3d00dc3a381

Exploring the Role of Salivary Biomarkers in Mild Traumatic Brain Injury Diagnosis

Abstract:
Mild Traumatic Brain Injury (mTBI) is a significant public health concern, with its diagnosis often hindered by subtle symptoms and limitations in traditional testing methods. Salivary biomarkers have emerged as a promising, non-invasive alternative for mTBI diagnosis. These biomarkers, including S100B protein, Neurofilament Light Chain (NfL), microRNAs (miRNAs), and extracellular vesicles (EVs), offer insights into neuroinflammatory processes and neuronal damage. Saliva’s accessibility and ease of collection position it as a cost-effective tool for early diagnosis and monitoring. Despite their potential, challenges such as standardization, biological complexity, and the need for validation persist. Advancements in research, technology, and integration with clinical tools could establish salivary biomarkers as a pivotal component in mTBI assessment, enabling more precise and personalized care.

Exploring the Role of Salivary Biomarkers in Mild Traumatic Brain Injury Diagnosis Read Post »

Scroll to Top